Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Aldrich to Acquire BioReliance

Published: Tuesday, January 10, 2012
Last Updated: Tuesday, January 10, 2012
Bookmark and Share
Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.

The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.  

BioReliance provides critical services that include biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers worldwide.  BioReliance's service offering helps facilitate biological drug development, manufacturing and commercialization activities. The Company's ability to develop and execute global testing protocols in compliance with various regulatory standards enables BioReliance's clients to register products worldwide.  The addition of these services is expected to result in a broader and richer value proposition for Sigma-Aldrich and have an immediate impact on its ability to provide enhanced solutions for its biopharmaceutical customers.  The advantage for the customer is the ability to work with a single point provider that is more vertically integrated throughout the drug discovery process.

BioReliance generated revenues of approximately $110 million in the year ended December 31, 2010 with double-digit growth expected in 2011.  The acquisition is expected to be modestly accretive to Sigma-Aldrich's diluted EPS in 2012 and enhance its already strong free cash flow.  BioReliance is headquartered in Rockville, Maryland with additional operations in Glasgow and Stirling, Scotland and sales offices in Tokyo and Bangalore. It employs over 650 people worldwide.

Commenting on the acquisition, President and CEO Rakesh Sachdev stated, "Our vision for Sigma-Aldrich is to enhance our Company's broad product offering and strong technology platforms with a compelling and specialized services platform.  The addition of BioReliance's industry-leading QA/QC testing services enables us to support customers' needs to determine the quality and integrity of biological drugs at every step of the development and manufacturing process.   As the market continues its focus on biological drug development, our leadership in this area should enable us to build even better, more customer-specific solutions. We are excited to add BioReliance's capabilities and its talented employees to our Company and fully expect its addition to contribute to our long-term growth and return goals."

Sigma-Aldrich expects to fund the acquisition with a combination of existing cash and credit facilities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SAFC Completes Manufacturing Expansion in St. Louis
Expansion to support commercial-scale antibody drug conjugate (ADC) manufacturing.
Saturday, May 16, 2015
SAFC Expands Carlsbad, Calif. Facility
Expansion to support commercial-scale gene therapy production, testing and filling.
Saturday, May 16, 2015
Sigma-Aldrich Expands in Singapore
New State-of-the-Art Technical Center, cGMP Distribution Center and Headquarters enhances ability to support customers in the region.
Monday, April 20, 2015
Sigma-Aldrich & Roche Enter Exclusive Distribution Agreement
Provides researchers with global access to Roche biochemical reagents product portfolio.
Thursday, March 19, 2015
Sigma and Czech Center for Phenogenomics Collaborate
Sigma-Aldrich® and the Institute of Molecular Genetics, Czech Center for Phenogenomics, establish CRISPR core lab collaboration.
Friday, January 30, 2015
SAFC’s Dry Powder Media Manufacturing Facility in Irvine, Scotland
Officially opens following extensive validation process.
Friday, January 23, 2015
Sigma-Aldrich Licenses Foundational CRISPR Patents from Broad Institute
Company is able to make, use and distribute the advanced gene editing tools for numerous research applications.
Tuesday, December 09, 2014
Sigma-Aldrich to Restructure Business into Three New Units
Sigma-Aldrich has provided the first details of a major restructuring that will align its organisation into three customer and market-focused business units.
Thursday, November 22, 2012
SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays
Companies to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology.
Friday, October 19, 2012
Biotech firm inks deal with Sigma-Aldrich
Henrietta-based biotechnology company Diffinity Genomics Inc. has inked a non-exclusive global distribution deal with Sigma-Aldrich Co. LLC, the local company said.
Wednesday, November 30, 2011
Hydrogen Storage Collaboration Between Sigma-Aldrich and Ilika Technologies to Scale-up and Commercialize Boron Hydride Materials
Materials show promise as high energy, low pressure hydrogen source.
Monday, July 25, 2011
Domainex Collaborates with Sigma-Aldrich to Advance the Study of Epigenetic Proteins Involved in Cancer and Stem Cell Biology
Domainex Ltd., have announced a collaboration with Sigma-Aldrich that will provide essential tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics.
Monday, November 15, 2010
Sigma® Life Science to Supply Oligonucleotides to Research Councils UK
A three-year contract with RCUK Shared Services Centre Limited to be a preferred supplier for synthetic oligonucleotides.
Monday, September 20, 2010
Sigma-Aldrich® Receives National Institutes of Health Funding for Cardiovascular Disease Research
Sigma® Life Science to analyze plasma samples from FHS in researching novel biomarkers for cardiovascular disease.
Monday, August 09, 2010
Sigma-Aldrich to Host Molecular Self-Assembly Webcast
November 17 Webcast Features MSA Scientific Leaders Professor Paul Weiss and Professor Milan Mrksich
Wednesday, November 11, 2009
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!